Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Laneshia K TagueDivision of Pulmonary and Critical Care, Department of Medicine, Washington University, St. Louis, Missouri. Electronic address: ltague@wustl.edu.
Hephzibah AnthonyDivision of Pulmonary and Critical Care, Department of Medicine, Washington University, St. Louis, Missouri.
Noha N SalamaSt. Louis College of Pharmacy at the University of Health Sciences and Pharmacy, St. Louis, Missouri.
Ramsey R HachemDivision of Respiratory, Critical Care and Occupational Pulmonary Medicine, Department of Internal Medicine, University of Utah, Salt Lake City, Utah.
Brian F GageDivision of General Medical Sciences, Department of Medicine, Washington University, St. Louis, Missouri.
Andrew E GelmanDivision of Cardiothoracic Surgery, Department of Surgery, Washington University, St. Louis, Missouri; Department of Pathology and Immunology, Washington University, St. Louis, Missouri.
Funding
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
The Role of Neutrophils in Regulating Lung Transplant ToleranceP01AI116501 · NIAID · WASHINGTON UNIVERSITY · PI Daniel Kreisel · 2015 to 2026
$19.4M
THE ROLE OF ISCHEMIA REPERFUSION INJURY IN LUNG ALLOGRAFT REJECTIONR01HL094601 · NHLBI · WASHINGTON UNIVERSITY · PI Andrew Eric Gelman, Daniel Kreisel · 2009 to 2026
$6.9M
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung TransplantationR33HL169189 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Derek E Byers, Andrew Eric Gelman · 2025 to 2026
$1.1M
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung TransplantationR61HL169189 · NHLBI · WASHINGTON UNIVERSITY · PI BYERS, DEREK E, GELMAN, ANDREW ERIC · 2023 to 2024
$655k
Influence of Mycophenolic Acid Pharmacogenomics on Lung Transplant OutcomesK01HL155231 · NHLBI · WASHINGTON UNIVERSITY · PI TAGUE, LANESHIA K · 2021 to 2024
backgroundMycophenolic Acid (MPA) is the most used anti-proliferative in lung transplantation, but its pharmacokinetic (PK) variability has precluded therapeutic drug monitoring. Both genetic and clinical factors have been implicated in MPA variability. This study aimed to integrate genetic and clinical factors with PK measurements to quantify MPA exposure.
methodsWe performed 12-hour pharmacokinetic analysis on 60 adult lung transplant recipients maintained on MPA for immunosuppression. We genotyped a SLCO1B3 polymorphisms previously associated MPA metabolism and collected relevant clinical data. We calculated area under the curve (AUC
resultsPK-only measurements obtained 2, 3, and 8 hours after MPA administration (C
conclusionsAn integrated limited sampling strategy (LSS) for MPA allows increased accuracy in prediction of MPA AUC
Indexed as
Drug MonitoringLung TransplantationMycophenolic AcidAdultFemaleGenotypeGraft RejectionHumansImmunosuppressive AgentsMaleMiddle AgedSolute Carrier Organic Anion Transporter Family Member 1B3Transplant RecipientsImmunosuppressive AgentsMycophenolic AcidSLCO1B3 protein, humanSolute Carrier Organic Anion Transporter Family Member 1B3limited sampling strategylung transplantationmycophenolic acidpharmacogeneticstherapeutic drug monitoring
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
An integrated sampling strategy for therapeutic mycophenolic acid monitoring in lung transplant recipients. · full record | OpenQuestion